A multicenter, randomized, double-blind, placebo controlled 36 week study to evaluate the efficacy and safety of extended release (ER) niacin/laropiprant in patients with type 2 diabetes.

Trial Profile

A multicenter, randomized, double-blind, placebo controlled 36 week study to evaluate the efficacy and safety of extended release (ER) niacin/laropiprant in patients with type 2 diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Hypercholesterolaemia; Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 24 Mar 2012 This trial is recruiting in (Finland) as reported by European Clinical Trials Database record.
    • 26 Sep 2010 Results have been presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
    • 15 Sep 2009 Actual number of patients (796) added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top